Details for New Drug Application (NDA): 062999
✉ Email this page to a colleague
NDA 062999 describes E-BASE, which is a drug marketed by Barr and is included in three NDAs. Additional details are available on the E-BASE profile page.
The generic ingredient in E-BASE is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
The generic ingredient in E-BASE is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
Summary for 062999
| Tradename: | E-BASE |
| Applicant: | Barr |
| Ingredient: | erythromycin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062999
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | 500MG | ||||
| Approval Date: | Nov 25, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
